CITI Program and Biotility at UF Announce Partnership
The Collaborative Institutional Training Initiative (CITI Program), the leader in online research, ethics, and compliance training, and Biotility at the University of Florida announced an exclusive licensing agreement to offer select Biotility’s biotech training courses on CITI Program’s learning platform.
BioFlorida Celebration of Biotechnology Shines a Light on the Future of the City of Alachua
BioFlorida held its Celebration of Biotechnology today behind the new AGTC buildings on US Hwy 441 in Alachua, just across from Progress Park, highlighting the future plans for the area that will be known as the Progress District. The Celebration was the first since 2019.
RTI Surgical Is Growing Its Footprint in Progress Park as the Biotech Industry Continues To Develop in Alachua
The biotech industry is expanding in Alachua, and companies are moving to North Central Florida from across the country. Mayor Gib Coerper of the City of Alachua said the growth in the life sciences industry is on a roll across the city.
Florida Institute and MPWRM Resource Center Fund Amend Surgical
UF Innovate | Sid Martin Biotech alum Amend Surgical, Inc., an Alachua-based medical device company, announced that it has finalized a funding agreement with the Institute for Commercialization of Florida Technology (the Florida Institute) along with being awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center.
Entrinsic Bioscience Steps Closer to Amino Acid Formulation as Therapy for Cystic Fibrosis
Entrinsic Bioscience and its licensee Nuvara Therapeutics announce they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations
Entrinsic Bioscience Announces Tool with Potential for Development of New Therapies Addressing Constipation
Entrinsic Bioscience announces a tool to measure intestinal peristalsis that could lead to the development of therapeutic agents for constipation, including Irritable Bowel Syndrome-Constipation (IBS-C).
Oragenics Extends Collaboration To Develop Vaccines Against Future Variants of Coronaviruses
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine
Surgalign Appoints David Lyle As Chief Financial Officer
Surgalign Holdings, a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. Surgalign acquired UF startup and Sid Martin Biotech alum RTI Surgical in 2020.
Covid-19 Nasal Vaccine Produces Antibodies, Cuts Viral Load
Tests with lab animals show a vaccine given as a nasal spray produces high antibody volumes against SARS-CoV-2 infections and reduces viral loads. Results of tests by biotechnology companies Oragenics Inc., a Sid Martin Biotech alum located in Tampa, and Inspirevax in Laval, Quebec, with National Research Council of Canada, appear on the bioRxiv pre-publication server, and are not yet peer-reviewed.
